Role of the cellular microRNA, miR-155, in EBV type III latency signaling
细胞 microRNA miR-155 在 EBV III 型潜伏信号传导中的作用
基本信息
- 批准号:8060608
- 负责人:
- 金额:$ 29.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-07-01 至 2014-04-30
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAddressApoptosisB-Cell ActivationB-Cell LymphomasBiologyBurkitt LymphomaCellsCloningData AnalysesDevelopmentElementsEpstein-Barr Virus latencyGene ExpressionGene TargetingGenesGeneticGrowthHerpesviridaeHodgkin DiseaseHomologous GeneHumanHuman Herpesvirus 4ImmuneIndividualKaposi SarcomaKnock-outMalignant NeoplasmsMediatingMicroRNAsMusMutationNasopharynx CarcinomaNon-Hodgkin&aposs LymphomaOncogenicPaperPatientsPlayPopulationPredispositionProbabilityProteinsReagentRoleSignal TransductionSignal Transduction PathwayTransforming Growth Factor betaUntranslated RegionsValidationbasecancer cellinhibitor/antagonistneoplastic cellprogramspublic health relevanceresponsetumorigenesis
项目摘要
DESCRIPTION (provided by applicant): The Epstein Barr virus (EBV) is an oncogenic herpesvirus that is intimately involved in a number of malignancies in humans. The genetic basis of EBV associated oncogenesis is the concerted action of EBV latency associated genes and varying cellular genetic alterations. In immuno-competent individuals only minimal EBV latency gene expression can be tolerated due to the immunogeneticity of several EBV encoded latency gene products. In AIDS patients, however, expression of the full repertoire of latency genes (referred to as type III latency) can sometimes be tolerated and expression of these genes provide many essential elements of tumor cell development. In this setting, fewer cellular genetic alterations are required to give rise to malignant cell populations and this probably partly explains the greatly increased susceptibility of AIDS patients to EBV associated non-Hodgkin's lymphomas. The cellular microRNA, miR-155, is one of the most highly implicated microRNAs in cancer. miR-155 is induced by the EBV type III latency program (but not the type I latency program) suggesting a possible role for miR-155 in modulating type III latency signal transduction. Further evidence that miR-155 signaling is relevant to herpesvirus biology has been provided by Rolf Renne's lab and by Bryan Cullen's lab who both showed recently that the Kaposi's Sarcoma Herpes virus (KSHV) encodes a functional homologue of miR- 155. Two mouse miR-155 knock out papers recently showed that miR-155 is important for B cell activation responses following immune challenge. We hypothesize that induction of miR-155 by EBV type III latency plays a role in facilitating EBV mediated B cell activation and that miR-155 modulates signal transduction pathways that contribute to EBV associated maligancies in AIDS patients. PUBLIC HEALTH RELEVANCE: EBV is associated with a number of human cancers including nasopharyngeal carcinoma, Hodgkin's lymphoma, Burkitt's lymphoma as well as a number of B-cell lymphomas in AIDS patients. Our studies are aimed at addressing the role of an oncogenic cellular microRNA, miR-155, that is induced by EBV latency genes expressed in AIDS associated malignancies.
描述(申请人提供):爱泼斯坦-巴尔病毒(EBV)是一种致癌性疱疹病毒,与人类的许多恶性肿瘤密切相关。EBV相关肿瘤发生的遗传学基础是EBV潜伏期相关基因和不同细胞遗传学改变的协同作用。在有免疫能力的个体中,由于几种EBV编码的潜伏期基因产物的免疫遗传性,只能耐受最低限度的EBV潜伏期基因表达。然而,在艾滋病患者中,所有潜伏期基因的表达(称为III型潜伏期)有时是可以容忍的,这些基因的表达提供了许多肿瘤细胞发育的基本要素。在这种情况下,需要较少的细胞遗传改变才能引起恶性细胞群,这可能部分解释了艾滋病患者对EBV相关的非霍奇金淋巴瘤的易感性大大增加。细胞microRNA miR-155是与癌症关系最密切的microRNA之一。MiR-155是由EBV III型潜伏期程序(而不是I型潜伏期程序)诱导的,这表明miR-155可能在调制III型潜伏期信号转导中发挥作用。Rolf Renne的实验室和Bryan Cullen的实验室提供了miR-155信号与疱疹病毒生物学相关的进一步证据,他们最近都表明Kaposi的肉瘤疱疹病毒(KSHV)编码miR-155的功能同源物。最近发表的两篇小鼠miR-155基因敲除论文表明,miR-155在免疫攻击后的B细胞激活反应中起重要作用。我们假设,EBV III型潜伏期诱导miR-155在促进EBV介导的B细胞激活中发挥作用,并且miR-155调节信号转导通路,从而促进艾滋病患者EBV相关性恶性疾病的发生。公共卫生相关性:EB病毒与许多人类癌症有关,包括鼻咽癌、霍奇金淋巴瘤、伯基特淋巴瘤以及艾滋病患者的一些B细胞淋巴瘤。我们的研究旨在解决致癌细胞microRNA miR-155的作用,它是由在艾滋病相关恶性肿瘤中表达的EBV潜伏基因诱导的。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ERIK K FLEMINGTON其他文献
ERIK K FLEMINGTON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ERIK K FLEMINGTON', 18)}}的其他基金
EBV reactivation causes widespread host de novo promoter transcription and transcriptional interference
EBV 重新激活导致广泛的宿主从头启动子转录和转录干扰
- 批准号:
10647826 - 财政年份:2022
- 资助金额:
$ 29.99万 - 项目类别:
EBV reactivation causes widespread host de novo promoter transcription and transcriptional interference
EBV 重新激活导致广泛的宿主从头启动子转录和转录干扰
- 批准号:
10548370 - 财政年份:2022
- 资助金额:
$ 29.99万 - 项目类别:
Programmed splicing derangement as new EBV host cell shut-off mechanism
程序性剪接紊乱作为新的 EBV 宿主细胞关闭机制
- 批准号:
10580068 - 财政年份:2022
- 资助金额:
$ 29.99万 - 项目类别:
Programmed splicing derangement as new EBV host cell shut-off mechanism
程序性剪接紊乱作为新的 EBV 宿主细胞关闭机制
- 批准号:
10446536 - 财政年份:2022
- 资助金额:
$ 29.99万 - 项目类别:
RPMS1 circular RNAs in EBV malignancies
EBV 恶性肿瘤中的 RPMS1 环状 RNA
- 批准号:
10397562 - 财政年份:2019
- 资助金额:
$ 29.99万 - 项目类别:
RPMS1 circular RNAs in EBV malignancies
EBV 恶性肿瘤中的 RPMS1 环状 RNA
- 批准号:
10612751 - 财政年份:2019
- 资助金额:
$ 29.99万 - 项目类别:
RPMS1 circular RNAs in EBV malignancies
EBV 恶性肿瘤中的 RPMS1 环状 RNA
- 批准号:
10153734 - 财政年份:2019
- 资助金额:
$ 29.99万 - 项目类别:
Project 2: Joint Transcriptomic and Epigenomic Studies for Male Osteoporosis
项目2:男性骨质疏松症的转录组和表观基因组联合研究
- 批准号:
10180819 - 财政年份:2017
- 资助金额:
$ 29.99万 - 项目类别:
"Core B" Viral RNA-seq and bioinformatics Core
“核心 B”病毒 RNA-seq 和生物信息学核心
- 批准号:
10403019 - 财政年份:2017
- 资助金额:
$ 29.99万 - 项目类别:
"Core B" Viral RNA-seq and bioinformatics Core
“核心 B”病毒 RNA-seq 和生物信息学核心
- 批准号:
10646252 - 财政年份:2017
- 资助金额:
$ 29.99万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 29.99万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 29.99万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 29.99万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 29.99万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 29.99万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 29.99万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 29.99万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 29.99万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 29.99万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 29.99万 - 项目类别:
Research Grant